Επειδή έτσι όπως έχει τεθεί, μπορεί να δημιουργηθεί σύγχυση (ειδικά αν απομονωθεί ως φράση), το: "οι λεσβίες π.χ. παρουσιάζουν, όπως είπαμε, αυξημένα ποσοστά CAH", στην σημαίνει: μεγαλύτερος αριθμός λεσβιών, σε σχέση με ετεροφυλόφιλες γυναίκες, έχουν CAH.Πάντως το CAH θα έλεγα ότι έχει πρωτίστως συνδεθεί με περιπτώσεις intersex/μεσοφυλικών ατόμων, με ΧΧ χρωμοσώματα:"Congenital Adrenal Hyperplasia (CAH)Congenital Adrenal Hyperplasia (CAH) is the most prevalent cause of intersex among people with XX chromosomes. About 1 in 10,000 to 18,000 children are born with congenital adrenal hyperplasia, but it does not cause intersex in those with XY chromosomes, so the prevalence of CAH-related intersex is about 1 in 20,000 to 1 in 36,000"http://www.isna.org/faq/conditions/cah…και οι "πολέμιοι" του βιολογικού ντετερμινισμού, αλλά και κάποιοι ερευνητές δεν θα έλεγα πως είναι και τόσο παράλογοι που ανησυχούν (στο άκουσμα prenatal Dexamethasone administration) και οι λόγοι δεν είναι μόνον «ιδεολογικοί»."Medical treatment carries possible side effect of limiting homosexualityA prenatal pill for congenital adrenal hyperplasia (CAH) to prevent ambiguous genitalia may reduce the chance that a female with the disorder will be gay. Critics call it engineering for sexual orientation".http://articles.latimes.com/2010/aug/15/science/la-sci-adrenal-20100815και“The prenatal administration of dexamethasone, a potent synthetic steroid of the glucocorticoid class, cannot prevent an affected child from being born with CAH. The intervention is aimed instead at causing CAH-affected female fetuses to develop in a more female-typical fashion than they otherwise might. Androgens contribute to sex differentiation, including in the brain and genitals; relatively low prenatal levels ordinarily result in a more female-typical development; relatively high levels usually result in male-typical development. In certain forms of CAH—including 21-hydroxylase deficiency (21-OHD CAH), i.e., the type of CAH most at issue here—the prenatal production of high levels of androgens may result in a genetic female (46,XX) fetus developing along a more masculine pathway neurologically and genitally. Prenatal dexamethasone is meant to engineer the CAH-affected female fetus’s hormonal system to be typically female.”“In the United States, the use of prenatal dexamethasone remains “off-label.” This means that the indication has never received approval by the Food and Drug Administration (FDA).1 Nonetheless, we want to be clear: The problem we see with the use of prenatal dexamethasone for CAH is not per se that it is an off-label use; it is rather that—as this paper documents—prenatal dexamethasone for CAH has sometimes been promoted to prospective patients and clinicians in misleading ways, and sometimes promoted for uses that are not legitimately medical (e.g., for the prevention of tomboyism and lesbianism).https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416978/και "Dexamethasone is used as an off-label early pre-natal treatment for the symptoms of CAH in female fetuses, but it does not treat the underlying congenital disorder. A 2007 Swedish clinical trial found that treatment may cause cognitive and behavioural defects, but the small number of test subjects means the study cannot be considered definitive. A 2012 American study found no negative short term outcomes, but "lower cognitive processing in CAH girls and women with long-term DEX exposure." Administration of pre-natal dexamethasone has been the subject of controversy over issues of informed consent and because treatment must predate a clinical diagnosis of CAH in the female fetus, especially because in utero dexamethasone may cause metabolic problems that are not evident until later in life; Swedish clinics ceased recruitment for research in 2010."https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia#Treatment